We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Nanoparticle Created for Cancer Therapy

By LabMedica International staff writers
Posted on 29 Apr 2014
Print article
Image: X-ray destruction of human breast cancer cells using Cu-Cy particles. The images show the live cancer cells stained green and the dead cells stained red (Photo courtesy of Wei Chen/UT Arlington).
Image: X-ray destruction of human breast cancer cells using Cu-Cy particles. The images show the live cancer cells stained green and the dead cells stained red (Photo courtesy of Wei Chen/UT Arlington).
A physicist working to create a luminescent nanoparticle to use in security-related radiation detection may have instead developed a new tool for photodynamic cancer therapy.

Wei Chen, professor of physics and co-director of University of Texas (UT) at Arlington (USA) Center for Security Advances Via Applied Nanotechnology, was testing a copper-cysteamine (Cu-Cy) complex created in his lab when he discovered mysterious decreases in its luminescence, or light emitting power, over a time-lapse exposure to X-rays. Researching further, he discovered that the nanoparticles, called Cu-Cy, were losing energy as they emitted singlet oxygen—a toxic byproduct used to damage cancer cells in photodynamic therapy.

Because Prof. Chen also is leading federally funded cancer research, he knew he had found something unique. Testing revealed that the Cu-Cy nanoparticles, combined with X-ray exposure, significantly slowed tumor growth in lab studies. “This new idea is simpler and better than previous photodynamic therapy methods. You don’t need as many steps. This material alone can do the job,” Prof. Chen said. “It is the most promising thing we have found in these cancer studies and we’ve been looking at this for a long time.”

Prof. Chen’s research will be published in the August 2014 edition of the Journal of Biomedical Nanotechnology. The article was published online April 2014. The University has also filed a provisional patent application on the new complex.

Photodynamic therapy (PDT) harms cancer cells when a photosensitizer introduced into tumor tissue produces toxic singlet oxygen after being exposed to light. In some studies, this light exposure is done through use of visible or near-infrared lasers. Others have found more success by also introducing luminescent nanoparticles into the tumor. Researchers activate the luminescent nanoparticle with near-infrared light or X-rays, which in turn activates the photosensitizer.

Both techniques have limitations for treating deep tissue cancers. They are either ineffective or the light source needed to activate them does not penetrate deep enough. Prof. Chen reported that X-ray-inducible Cu-Cy particles surpass current photosensitizers because the X-rays can penetrate deep into tissue. Furthermore, Cu-Cy nanoparticles do not need other photosensitizes to be effective so the treatment is more convenient, efficient and cost-effective.

“Dr. Chen’s commitment to his work in cancer-related therapy, as well as his work in the area of homeland security, demonstrates the wide-ranging applications and great value of basic science research,” said Carolyn Cason, vice president for research at UT Arlington. “These advances have the potential to change the way some cancers are treated and make therapy more effective—a benefit that would be boundless.”

Prof, Chen’s team assessed the Cu-Cy on human breast and prostate cancer cells in the lab and found it to be an effective treatment when combined with X-ray exposure. In one esperiment, for example, a tumor treated with Cu-Cy injection and X-ray exposure stayed virtually the same size over a 13-day period while a tumor without the full treatment grew by three times.

Another benefit of the new nanoparticle is a low toxicity to healthy cells. Furthermore, Cu-Cy’s intense photoluminescence and X-ray luminescence can be employed for cell imaging, according to the scientists. Details of the crystal structure and optical characteristics of the new complex are slated for publication in an upcoming paper from the Journal of Materials Chemistry. Prof. Chen reported that additional research would include reducing the size of the Cu-Cy nanoparticle to make it more easily absorbed in the tumor tissue. “For cancer, there is still no good solution yet. Hopefully this nanoparticle can provide some possibilities,” he said.

Related Links:

University of Texas at Arlington


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.